رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06589986 (Ametrine-1) لـ التهاب القولون التقرحي النشط بشكل متوسط إلى شديد هي نشط (لا يقبل مشاركين جدد). اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
دراسة واحدة تطابق معايير الفلتر
عرض البطاقة
العودة إلى البحث
هوفمان-لا روشA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1) المرحلة الثالثة ٤٠٠ مزدوجة التعمية مضبطة بدواء وهمي
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ رادار التجارب AI مساعدتك؛ ما عليك سوى النقر على «وصف الدراسة» لعرض ومناقشة معلومات الدراسة باللغة التي اخترتها.
التجربة السريرية NCT06589986 (Ametrine-1) مصممة لدراسة علاج لـالتهاب القولون التقرحي النشط بشكل متوسط إلى شديد. إنها دراسة تدخُّلية من المرحلة الثالثة وهي نشط (لا يقبل مشاركين جدد). بدأت في ١٤ ربيع الأول ١٤٤٦ هـ مع خطة لتجنيد ٤٠٠ مشاركًا. تقودها هوفمان-لا روش، ومن المتوقع اكتمالها بحلول ٧ شوال ١٤٥٢ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٣٠ رمضان ١٤٤٧ هـ.
الملخص
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
العنوان الرسمي
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
الحالات الطبية
التهاب القولون التقرحي النشط بشكل متوسط إلى شديدمعرّفات دراسة أخرى
- Ametrine-1
- GA45329
- 2024-513014-35-00 (رقم دراسة الاتحاد الأوروبي (CTIS))
NCT معرّف
تاريخ البدء (فعلي)
2024-09-17
آخر تحديث مُنشور
2026-03-19
تاريخ الاكتمال (المقدر)
2031-01-30
عدد المشاركين المخطط لهم
٤٠٠
نوع الدراسة
تدخُّلية
المرحلة
المرحلة الثالثة
الحالة
نشط (لا يقبل مشاركين جدد)
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
مزدوج
مجموعات/التدخلات
| مجموعة المشاركين/الذراع | التدخل/العلاج |
|---|---|
تجريبيةAfimkibart Participants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection. | Afimkibart Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection. |
مقارن بالدواء الوهميPlacebo Participants will receive placebo IV followed by placebo SC. | دواء وهمي Placebo matching IV afimkibart. Placebo matching SC afimkibart. |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Percentage of Participants with Clinical Remission at Week 12 | Percentage of participants achieving Modified Mayo Score (mMS) \<=2 with stool frequency subscore (SFS) = 0 or 1 (up to 1-2 stools more than normal), rectal bleeding subscore (RBS) = 0 (no blood seen) and endoscopic subscore (ES) = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | At Week 12 |
Percentage of Participants with Clinical Remission at Week 52 | Percentage of participants achieving mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | At Week 52 |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Change in Partial Modified Mayo Score (pmMS) | Change in pmMS from baseline to Week 2. pmMS is a composite score of ulcerative colitis signs and symptoms activity given by the sum of the SFS and RBS. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed). | Baseline to Week 2 |
Percentage of Participants with Endoscopic Improvement | Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. | At Week 12 |
Percentage of Participants with Endoscopic Remission | Percentage of participants achieving endoscopic subscore of 0 (normal appearance of mucosa) at Week 12. | At Week 12 |
Percentage of Participants with Clinical Response | Percentage of participants achieving a decrease in mMS of at least 2 points and 30% from baseline and either a decrease in RBS \>= 1 or RBS = 0 or 1 (no blood seen or stool with streaks of blood) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed). ES is measured on a scale from 0 (normal appearance of mucosa) to 3 (severe disease). | At Week 12 |
Percentage of Participants with Histologic Improvement | Percentage of participants achieving a histologic improvement, defined as Geboes \<=3.1 at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 12 |
Percentage of Participants with Histologic Remission | Percentage of participants achieving a histologic remission, defined as Geboes \<2B at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 12 |
Percentage of Participants with Histologic-Endoscopic Mucosal Improvement | Percentage of participants achieving Geboes \<= 3.1 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 12 |
Percentage of Participants with Histologic-Endoscopic Remission | Percentage of participants achieving Geboes \< 2 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 12 |
Percentage of Participants with Maintenance of Remission | Percentage of participants with clinical remission at both Week 12 and Week 52. Clinical remission is defined as mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | Week 12 and Week 52 |
Percentage of Participants with Corticosteroid-Free Remission | Percentage of participants in clinical remission at Week 52 with no corticosteroid use at least 8 weeks prior to Week 52. Clinical remission is defined as mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | At Week 52 |
Percentage of Participants with Endoscopic Improvement | Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. | At Week 52 |
Percentage of Participants with Endoscopic Remission | Percentage of participants achieving endoscopic subscore of 0 (normal appearance of mucosa) at Week 52. | At Week 52 |
Percentage of Participants with Histologic Improvement | Percentage of participants achieving histologic improvement defined as Geboes \<= 3.1 at Week 52. | At Week 52 |
Percentage of Participants with Histologic Remission | Percentage of participants achieving histologic remission defined as Geboes \<2B at Week 52. | At Week 52 |
Percentage of Participants with Histologic-Endoscopic Mucosal Improvement | Percentage of participants achieving Geboes \<= 3.1 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 52 |
Percentage of Participants with Histologic-Endoscopic Remission | Percentage of participants achieving Geboes \< 2 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue). | At Week 52 |
Percentage of Participants with Clinical remission: Among Biomarker-Defined Subgroups of Participants | Percentage of participants achieving mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12 in biomarker-defined subgroups. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | At Week 12 |
Percentage of Participants with Clinical remission: Among Biomarker-Defined Subgroups of Participants | Percentage of participants achieving mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity. | At Week 52 |
Percentage of Participants with Endoscopic Improvement: Among Biomarker-Defined Subgroups of Participants | Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 12 in biomarker-defined subgroups. | At Week 12 |
Percentage of Participants with Endoscopic Improvement: Among Biomarker-Defined Subgroups of Participants | Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups. | At Week 52 |
Change in Bowel Urgency | Change in bowel urgency from baseline through Week 52. Bowel urgency is measured on a scale from 0 (None) to 4 (Severe). | Baseline through Week 52 |
Change in Abdominal Pain | Change in abdominal pain from baseline through Week 52. Abdominal pain is measured on a scale from 0 (None) to 4 (Severe). | Baseline through Week 52 |
Change in Fatigue | Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) from baseline to Week 12 and Week 52. FACIT-Fatigue is a 13-item self-reported assessment of the level and impact of fatigue. The overall FACIT-Fatigue score ranges between 0 and 52, with higher scores associated with better quality of life concerns related to fatigue. | Baseline to Week 12 and Week 52 |
Change in Health-Related Quality of Life | Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline to Week 12 and Week 52. IBDQ is a 32-item self-reported assessment of health-related quality of life in participants with inflammatory bowel disease. The overall IBDQ score ranges from 32 to 224, with higher scores associated with better health-related quality of life. | Baseline to Week 12 and Week 52 |
Overall Change in UC Symptoms | Patient Global Impression of Change (PGIC) from baseline to Weeks 2, 12 and 52. PGIC measures overall change in ulcerative colitis symptoms from "Much better" to "Much worse". | Baseline to Week 2, Week 12, and Week 52 |
Overall Severity in UC Symptoms | Patient Global Impression of Severity (PGIS) from baseline to Weeks 2, 12 and 52. PGIS measures severity of ulcerative colitis symptoms from "None" to "Very severe". | Baseline to Week 2, Week 12, and Week 52 |
Incidence and Severity of Adverse Events (AEs) | Incidence and severity of AEs, including serious AEs, AEs leading to treatment discontinuation and AEs of special interest. | Up to 70 Weeks after Baseline |
مساعد المشاركة
معايير الأهلية
الأعمار المؤهلة للدراسة
طفل, بالغ, كبار السن
العمر الأدنى للدراسة
16 Years
الجنس المؤهل
الكل
- Confirmed diagnosis of UC
- Moderately to severely active UC assessed by mMS
- Bodyweight >= 40 kilogram (kg)
- Up to date with colorectal cancer (CRC) screening performed according to local standards
- Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced UC therapy
- Males and females of childbearing potential must meet protocol criteria for contraception requirements
- Currently known complications of UC (e.g. fulminant colitis, toxic megacolon)
- Current diagnosis of Crohn's disease (CD) or indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis
- Presence of an ostomy or ileoanal pouch
- Current diagnosis or suspicion of primary sclerosing cholangitis
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- Past or current evidence of definite low-grade or high-grade colonic dysplasia or adenomas or neoplasia not completely removed
- History of malignancy within 5 years, with the exception of malignancies adequately treated with resection for non-metastatic basal cell or squamous cell cancer or in situ cervical cancer
- Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV)
- Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB
- Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy
هوفمان-لا روشتشوغاي الصيدلانية27 دراسات نشطة للاستكشافلا توجد بيانات اتصال.
229 مواقع الدراسة في 31 بلدان
Alabama
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama, 36305, United States
Arizona
Arizona Digestive Health, P.C (ADH), Sun City, Arizona, 85351, United States
California
Om Research LLC, Lancaster, California, 93534, United States
UCLA, Los Angeles, California, 90095, United States
University of California Irvine, Orange, California, 92868, United States
Stanford Medicine Outpatient Center, Redwood City, California, 94063, United States
Acclaim Clinical Research, Inc., San Diego, California, 92120, United States
UCSF/Medical Center at Mount Zion, San Francisco, California, 94115, United States
Amicis Research Center, Santa Clarita, California, 91355, United States
Colorado
Peak Gastroenterology Associates, Colorado Springs, Colorado, 80907, United States
Peak Gastroenterology Surgery Center, Lone Tree, Colorado, 80124, United States
Florida
Access Research Institute, Brooksville, Florida, 34613, United States
Gastro Florida, Clearwater, Florida, 33756, United States
HealthMed Clinical Center Inc., Coral Gables, Florida, 33134, United States
J&A Clinical Research, Doral, Florida, 33126, United States
Clinical Research of Osceola, LLC, Kissimmee, Florida, 34741, United States
Auzmer Research, Lakeland, Florida, 33813, United States
Florida Research Institute - Lakewood, Lakewood Rch, Florida, 34211, United States
Homestead Associates in Research, Inc., Miami, Florida, 33033, United States
Allied Biomedical Research Institute, Inc, Miami, Florida, 33155, United States
Miami Beach Clinical Research Center, Miami Beach, Florida, 33141, United States
Eminat Research Group, Miramar, Florida, 33027, United States
Orlando Regional Healthcare, Orlando, Florida, 32806, United States
Nodal Medical Center, LLC, Tampa, Florida, 33607, United States
Theia Clinical Research Centers, LLC, Tampa, Florida, 33613, United States
Cleveland Clinic Florida, Weston, Florida, 33331, United States
Florida Medical Clinic, Zephyrhills, Florida, 33542, United States
Georgia
Gastroenterology Associates of Central Georgia, Macon, Georgia, 31201, United States
Idaho
Grand Teton Research Group, PLLC, Idaho Falls, Idaho, 83404, United States
Illinois
Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States
Next Innovative Clinical Research, Chicago, Illinois, 60616, United States
The University of Chicago, Chicago, Illinois, 60637, United States
Indiana
Indiana University Health University Hospital, Indianapolis, Indiana, 46202, United States
Gastroenterology Health Partners, PLLC, New Albany, Indiana, 47150, United States
Kentucky
Tri-State Gastroenterology Associates, Crestview Hills, Kentucky, 41017-3409, United States
Robley Rex VA Medical Center, Louisville, Kentucky, 40206, United States
Gastroenterology Health Partners, PLLC, Louisville, Kentucky, 40218, United States
Louisiana
Louisiana Research Center - GastroIntestinal Associates, Shreveport, Louisiana, 71105, United States
Massachusetts
Brigham & Womens Hosp, Boston, Massachusetts, 02115, United States
Boston University, Boston, Massachusetts, 02118, United States
Michigan
Michigan Center of Medical Research, Farmington Hills, Michigan, 48334, United States
Mississippi
Allied Gastrointestinal Associates, PA, Flowood, Mississippi, 39232, United States
Missouri
BVL Clinical Research, Liberty, Missouri, 64068, United States
Nevada
Las Vegas Clinical Trials, LLC, North Las Vegas, Nevada, 89030, United States
New York
Intercity Gastroenterology, Fresh Meadows, New York, 11366, United States
Northwell Health Physician Partners Gastroenterology at Great Neck, Great Neck, New York, 11021, United States
Pioneer Clinical Research NY, New York, New York, 10016, United States
Mainstreet - Richmond Hill Clinic, Richmond Hill, New York, 11418, United States
North Carolina
Digestive Health Partners, PA, Asheville, North Carolina, 28801, United States
Peters Medical Research (PMR), LLC, High Point, North Carolina, 27260, United States
Monroe Biomedical Research, Monroe, North Carolina, 28112, United States
Ohio
Digestive Disease Consultants, Brunswick, Ohio, 44212, United States
Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States
Ohio Gastroenterology Group, Columbus, Ohio, 43202, United States
Great Lakes Gastroenterology Research, LLC, Mentor, Ohio, 44060, United States
Gastro Intestinal Research Institute of Northern Ohio, Westlake, Ohio, 44145, United States
Rhode Island
University Gastroenterology, Providence, Rhode Island, 02904, United States
South Carolina
Medical University of South Carolina (MUSC), Charleston, South Carolina, 29425, United States
Tennessee
Gastro One, Cordova, Tennessee, 38018, United States
Gastrointestinal Associates of Northeast Tennessee, Johnson City, Tennessee, 37604, United States
Quality Medical Research, Nashville, Tennessee, 37211, United States
Texas
Texas Digestive Disease Consultants - Cedar Park, Cedar Park, Texas, 78613, United States
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, United States
Proactive El Paso,LLC, El Paso, Texas, 79902, United States
GI Alliance, Garland, Texas, 75044, United States
Baylor College of Medicine., Houston, Texas, 77030, United States
TDDC dba GI Alliance Research, Mansfield, Texas, 76063, United States
SMS Clinical Research, LLC, Mesquite, Texas, 75149, United States
Digestive System Healthcare - Biopharma Informatic, LLC, Pasadena, Texas, 77505-3950, United States
Carta - Clinical Associates In Research Therapeutics Of America;LLC, San Antonio, Texas, 78212, United States
Southern Star Research Institute, LLC., San Antonio, Texas, 78229, United States
GI Alliance - Southlake, Southlake, Texas, 76092, United States
Tyler Research Institute, LLC, Tyler, Texas, 75701, United States
University of Texas Health Center at Tyler, Tyler, Texas, 75708, United States
Virginia
Tidewater Gastroenterology Pllc T/A Gastro. Assoc. of Tidewater, Chesapeake, Virginia, 23320, United States
Gastroenterology Consultants of SWVA, Roanoke, Virginia, 24018, United States
Washington
The Vancouver Clinic, Vancouver, Washington, 98664, United States
West Virginia
Marshall Health, Huntington, West Virginia, 25701, United States
Wisconsin
Univ of Wisconsin Hosp & Clin, Madison, Wisconsin, 53792, United States
CIPREC Centro de Investigacion y Prevencion Cardiovascular, Ciudad Autonoma Buenos Aires, C1061AAS, Argentina
Expertia S.A- Mautalen Salud e Investigación, Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
Australian Capital Territory
The Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia
New South Wales
Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia
Queensland
Mater Misericordiae Limited, South Brisbane, Queensland, 4101, Australia
South Australia
Lyell McEwin Hospital, Adelaide, South Australia, 5112, Australia
Western Australia
Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia
Medizinische Universität Innsbruck, Innsbruck, 6020, Austria
Barmherzige Brüder Wien, Vienna, 1020, Austria
Medizinische Universität Wien, Vienna, 1090, Austria
AZ Maria Middelares, Ghent, 9000, Belgium
CHC MontLégia, Liège, 4000, Belgium
CHU de Liège (Sart Tilman), Liège, 4000, Belgium
Paraná
Centro Digestivo de Curitiba, Curitiba, Paraná, 80430-160, Brazil
Rio Grande do Sul
Hospital de Clinicas de Porto Alegre X, Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
São Paulo
CPQuali Pesquisa Clinica Ltda, São Paulo, São Paulo, 01228-000, Brazil
BR Trials - Pesquisa Clínica, São Paulo, São Paulo, 03325-050, Brazil
MHAT St. Ivan Rilski, Gorna Oryahovitsa, 5100, Bulgaria
Alberta
South Edmonton Gastroenterology, Edmonton, Alberta, T6K 4B2, Canada
Hospital Guillermo Grant Benavente, Concepción, 4030000, Chile
Clinica Universidad de Los Andes, Santiago, Chile
Medwal, Santiago, Chile
Peking University Third Hospital, Beijing, 100191, China
Binzhou Medical university hospital, Binzhou, China
the First Hospital of Jilin University, Changchun, 130021, China
Sichuan Provincial People's Hospital, Chengdu, 610072, China
The First Affiliated Hospital Of Fujian Medical University, Fuzhou, 350005, China
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China
The sixth affiliated hospital of Sun Yat-Sen University, Guangzhou, 510655, China
Anhui Provincial Hospital, Hefei, 230001, China
The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
Huizhou First Hospital, Huizhou, China
Jinhua municipal central hospital, Jinhua, China
The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, 330006, China
Nanjing 1st Hospital, Nanjing, 210006, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China
Peking University Shenzhen Hospital, Shenzhen, 518036, China
Hebei Medical University - The Second Hospital, Shijiazhuang, 050004, China
Tianjin Medical University General Hospital, Tianjin, 300052, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
Ren Min Hospital Affiliated Wu Han University, Wuhan, 430060, China
Wuxi People's Hospital, Wuxi, 214023, China
The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, 710004, China
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Zhuzhou Central Hospital, Zhuzhou, China
Borzan Polyclinic, Osijek, 31000, Croatia
SurGal Clinic s.r.o., Brno, 602 00, Czechia
Nemocnice Ceske Budejovice a.s., České Budějovice, 370 01, Czechia
Gastroenterologie s.r.o., Hradec Králové, 500 02, Czechia
Herlev Hospital, Herlev, 2730, Denmark
CHU Amiens - Hopital Sud, Amiens, 80054, France
CHU Dijon Bourgogne Hôpital François Mitterand, Dijon, 21000, France
CH Dptal Les Oudairies, La Roche-sur-Yon, 85925, France
CHRU de Lille - Hopital Claude Huriez, Lille, 59037, France
Hopital Nord, Marseille, 13015, France
Institut des MICI, Clinique Ambroise Paré, Neuilly-sur-Seine, 92200, France
CHU Nice - Hopital de l'Archet 2, Nice, 06202, France
CHU Bordeaux - Hôpital Haut-Lévêque, Pessac, 33604, France
Centre Hospitalier Lyon Sud, Pierre-Bénite, 69495, France
Hopital Robert Debre, Reims, 51092, France
CHU de Rennes - Hopital de Pontchaillo, Rennes, 35033, France
CHU Saint Etienne - Hôpital Nord, Saint-Etienne, 42055, France
Hôpital de Rangueil, Toulouse, 31400, France
Universitaetsklinikum Jena, Jena, 77430, Germany
Clinexpert Kft., Budapest, 1033, Hungary
Obudai Egeszsegugyi Centrum Kft., Budapest, 1036, Hungary
Pannonia Maganorvosi Centrum, Budapest, 1136, Hungary
Clinexpert Gyongyos Kft, Gyöngyös, 3200, Hungary
Clinfan Szolgaltato Kft., Szekszárd, 7100, Hungary
Jávorszky Ödön Kórház, Vác, 2600, Hungary
Gujarat
Surat Institute of Digestive Sciences Hospitals, Surat, Gujarat, 395002, India
Gujarat Gastro and Vascular Hospital, Surat, Gujarat, 395009, India
Rajasthan
SR Kalla Memorial Gastro & General Hospital, Jaipur, Rajasthan, 302006, India
Bayit Vegan
Shaare Zedek Medical Center, Jerusalem, Bayit Vegan, 9103102, Israel
Basilicate
Ospedale Madonna delle Grazie, Matera, Basilicate, 75100, Italy
Campania
Universita'degli Studi di Napoli Federico II, Naples, Campania, 80131, Italy
Lazio
Policlinico Universitario Agostino Gemelli, Rome, Lazio, 00168, Italy
Lombardy
Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Lombardy, 27100, Italy
ASST Rhodense - Ospedale di Rho, Rho, Lombardy, 20017, Italy
Tsujinaka Hospital Kashiwanoha, Chiba, 277-0871, Japan
Fukuoka University Hospital, Fukuoka, 814-0180, Japan
Hidaka Coloproctology Clinic, Fukuoka, 839-0809, Japan
Japanese Red Cross Takayama Hospital, Gifu, 506-8550, Japan
Aoyama Clinic;GI Endoscopy & IBD Center, Hyōgo, 650-0015, Japan
Kagawa Prefectural Central Hospital, Kagawa, 760-8557, Japan
Sameshima Hospital, Kagoshima, 892-0846, Japan
Gokeikai Ofuna Chuo Hospital, Kanagawa, 247-0056, Japan
Nagasaki University Hospital, Nagasaki, 852-8501, Japan
National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan
Ishida Clinic of IBD and Gastroenterology, Ōita, 870-0823, Japan
Saga-ken Medical Centre Koseikan, Saga, 840-8571, Japan
Saga University Hospital, Saga, 849-8501, Japan
National Hospital Organization Shizuoka Medical Center, Shizuoka, 411-8611, Japan
Matsuda Hospital, Shizuoka, 432-8061, Japan
Kitasato University Kitasato Institute Hospital, Tokyo, 108-8642, Japan
JCHO Tokyo Yamate Medical Center, Tokyo, 169-0073, Japan
Tokai University Hachioji Hospital, Tokyo, 192-0032, Japan
Yokohama City University Medical Center, Yokohama, 232-0024, Japan
Jalisco
Boca Clinical Trials Mexico S.C. (Guadalajara), Guadalajara, Jalisco, 44600, Mexico
Nuevo León
Accelerium S. de R.L. de C.V., Monterrey, Nuevo León, 64000, Mexico
Tlaxcala
Hospital General de Mexico, Mexico, Tlaxcala, 06726, Mexico
Yucatán
Medical Care & Research SA de CV, Mérida, Yucatán, 97000, Mexico
SPZOZ w ??cznej, ??czna, 21-010, Poland
Clinical Trials UMED Sp. z o. o., ?ód?, 92-213, Poland
Centrum Medyczne "Medis", Bydgoszcz, 85-229, Poland
Centrum Medyczne Lukamed Joanna Luka-Wendrowska, Chojnice, 89-600, Poland
Endo-Med Sp. z o.o., Karczew, 05-480, Poland
Allmedica Badania Kliniczne Sp z o.o. Sp K., Nowy Targ, 34-400, Poland
Wojewodzki Specjalistyczny Szpital w Olsztynie, Olsztyn, 10-561, Poland
NZOZ Eskulap Pabianice, Pabianice, 95-200, Poland
SOLUMED Centrum Medyczne, Późna, 60-529, Poland
Centrum Medyczne "MEDYK", Rzeszów, 35-326, Poland
Kiepury Clinic, Sosnowiec, 41-200, Poland
Gastromed Sp. z o.o., Toru?, 87-100, Poland
Centralny Szpital Kliniczny MSW w Warszawie, Warsaw, 02-507, Poland
WIP Warsaw IBD Point Profesor Kierkus, Warsaw, 04-501, Poland
Vistamed & Vertigo Spó?Ka Z Ograniczon? Odpowiedzialno?Ci?, Wroc?aw, 53-149, Poland
Penta Hospitals Przychodnie, Wroclaw Wejherowska, Wroc?aw, 54-239, Poland
Melita Medical, Wroclaw, 53-611, Poland
ETG Zamosc, Zamo??, 22-400, Poland
Hospital de Braga, Braga, 4710-243, Portugal
Hospital da Luz Lisboa, Lisbon, 1500-650, Portugal
Centro Hospitalar do Algarve - Hospital de Portimao, Portimão, 8500-338, Portugal
Hospital de Sao Joao, Porto, 4202-451, Portugal
Centro Hospitalar de Entre Douro e Vouga - H. São Sebastião, Santa Maria da Feira, 4520-211, Portugal
Hospital Sao Teotonio, Viseu, 3504-509, Portugal
University of Puerto Rico - Medical Science Campus, San Juan, 00936-5067, Puerto Rico
Colentina Clinical Hospital, Bucharest, 020125, Romania
Cantacuzino Clinical Hospital, Bucharest, 020475, Romania
University Hospital Center Dr Dragisa Misovic - Dedinje, Belgrade, 11040, Serbia
Clinical Hospital Center Zemun, Belgrade, 11080, Serbia
University Hospital Medical Center Bezanijska Kosa, Belgrade, 11080, Serbia
University Hospital Medical Center Zvezdara, Belgrade, 11120, Serbia
Clinical Center Kragujevac, Kragujevac, 34000, Serbia
Clinical Center of Vojvodina, Novi Sad, 21137, Serbia
Cliniq s.r.o., Bratislava, 811 09, Slovakia
Endomed, s.r.o., Košice, 040 01, Slovakia
Cantabria
Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain
Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain
Changhua County
Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua, Changhua County, 50006, Taiwan
Zhongzheng District
National Taiwan University Hospital, Taipei, Zhongzheng District, 100, Taiwan
Division of Gastroenterology, Depart of Medicine, Fac of Med., Chulalongkorn University, Bangkok, 10330, Thailand
Division of Gastroenterology, Depart of Internal Med, Siriraj H, Mahidol Uni, Bangkok, 10700, Thailand
Liver Research Unit, Srinagarind Hospital, Khon Kaen, 40002, Thailand
Thammasat University Hospital, Pathum Thani, 12120, Thailand
Division of Gastroenterology, Depart of Medicine, Fac. of Med, Songklanagarind University, Songkhla, 90110, Thailand
Surin hospital, Surin, 32000, Thailand
Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom
Royal Liverpool University Hospital, Liverpool, L7 8XP, United Kingdom
Guy's Hospital, London, SE1 9RT, United Kingdom